Pfizer Launches Biosimilar Trastuzumab In US
Rival To Herceptin Competes In An Increasingly Crowded Market
Pfizer has confirmed the launch of its Trazimera trastuzumab biosimilar in the US. The rival to Herceptin will compete against not only the brand but also against two other biosimilars, with more on the way.
